Skip to main content
Research:
Research
24 Nov 2021

COVID-19: Impact on Canada’s pharmaceutical and retail pharmacy industry

A view of the unique challenges and opportunities

Download the report
3 MB PDF
Contact us
Contact us


The coronavirus pandemic has affected Canada’s pharmaceutical and retail pharmacy industry across four main areas: product sourcing and procurement, product launch and distribution, acquisition and access, and treatment and care management. Based on challenges in these areas, this report offers a perspective on potential solutions and considerations.

Topics covered in this paper include:

  • How COVID-19 has affected the Canadian life sciences industry
  • Thinking through the unique challenges of COVID-19
  • Top challenges facing the industry
  • Opportunities to address key challenges and prepare for the future
  • Key considerations for successfully navigating through unprecedented times
Key contacts:
 

Shanil Ebrahim
Life Sciences & Health Care AI Leader

Rob Lanoue
Partner, Customer Insights Leader

Did you find this useful?

Yes
No

Thanks for your feedback

Our thinking

Consumers call for innovative transformation

Life and health insurance has long been regarded as a staid, highly traditional business. But significant change is in the air, according to our survey of Canadian senior insurance executives.
Research

COVID-19: Smart solutions for recovery

COVID-19 has pushed the health care industry to adapt to a quickly evolving landscape. To recover and then thrive, companies need to prepare for the long-term integration of some of the advanced data tools created during the pandemic.
Research

Lean in health care: Taking a patient-centred approach

For years, the health care industry has implemented a variety of approaches to identify appropriate ways to improve operations.
Research

Health care professionals payment transparency in Ontario

In passing the Health Sector Payment Transparency Act in 2017, Ontario became the first province to formally address the transparency of payments made by pharmaceutical and medical device companies to health care professionals.
Research
Explore our thinking